Hideshi Ishii Selected Research

Histidine (L-Histidine)

7/2009	Fragile gene product, Fhit, in oxidative and replicative stress responses.
12/2008	Identification of the expression profile of apoptotic esophageal cancer cells by adenoviral-fragile histidine triad treatment.
11/2004	Inactivation of the FHIT gene favors bladder cancer development.
4/2004	Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
3/2004	Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
11/2003	Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
11/2003	Alteration of the fragile histidine triad gene early in carcinogenesis: an update.
3/2003	Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines.
2/2003	Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding.
3/2002	Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideshi Ishii Research Topics

Disease

124	Neoplasms (Cancer) 10/2022 - 03/2002
35	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 07/2004
24	Neoplasm Metastasis (Metastasis) 10/2022 - 12/2004
13	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 11/2004
11	Stomach Neoplasms (Stomach Cancer) 05/2015 - 01/2006
9	Carcinogenesis 08/2018 - 01/2003
8	Breast Neoplasms (Breast Cancer) 01/2019 - 03/2003
6	Adenocarcinoma 10/2022 - 01/2013
6	Colonic Neoplasms (Colon Cancer) 01/2019 - 12/2008
6	Leukemia 02/2015 - 05/2003
6	Esophageal Neoplasms (Esophageal Cancer) 07/2013 - 10/2004
5	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 07/2021 - 08/2015
4	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 11/2012
4	Liver Neoplasms (Liver Cancer) 11/2012 - 09/2010
4	Lymphatic Metastasis 11/2010 - 09/2010
4	Carcinoma (Carcinomatosis) 05/2007 - 03/2002
3	Cholangiocarcinoma 03/2018 - 04/2010
3	Hypoxia (Hypoxemia) 02/2018 - 09/2010
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2016 - 10/2004
2	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2022 - 03/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 06/2005
2	Hematologic Neoplasms (Hematological Malignancy) 03/2015 - 10/2008
2	Inflammation (Inflammations) 05/2013 - 03/2006
2	Urinary Bladder Neoplasms (Bladder Cancer) 04/2008 - 11/2004

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 04/2022 - 05/2003
20	MicroRNAs (MicroRNA)IBA 05/2022 - 04/2011
16	Messenger RNA (mRNA)IBA 01/2022 - 11/2003
16	EnzymesIBA 10/2018 - 07/2004
11	RNA (Ribonucleic Acid)IBA 10/2021 - 10/2004
10	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2003
10	CarbonIBA 10/2021 - 11/2015
10	Biological ProductsIBA 06/2021 - 03/2003
10	Indicators and Reagents (Reagents)IBA 11/2015 - 01/2006
10	Histidine (L-Histidine)FDA Link 07/2009 - 03/2002
9	Pharmaceutical PreparationsIBA 02/2022 - 03/2014
7	CarcinogensIBA 06/2012 - 09/2003
6	Transcription Factors (Transcription Factor)IBA 01/2022 - 10/2011
6	Fluorouracil (Carac)FDA LinkGeneric 01/2018 - 09/2010
5	Folic Acid (Vitamin M)FDA LinkGeneric 07/2021 - 01/2017
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2007
4	Trifluridine (Viroptic)FDA LinkGeneric 01/2022 - 04/2017
4	6-methyladenineIBA 01/2022 - 01/2018
4	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2021 - 07/2012
4	Small Interfering RNA (siRNA)IBA 02/2018 - 03/2006
4	Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA 01/2018 - 03/2014
4	Pyruvate KinaseIBA 08/2015 - 10/2014
4	Complementary DNA (cDNA)IBA 06/2012 - 11/2004
4	fragile histidine triad proteinIBA 05/2007 - 03/2002
4	nitrosobenzylmethylamineIBA 03/2005 - 01/2003
3	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 12/2004
3	Gemcitabine FDA Link 01/2019 - 09/2015
3	Epidermal Growth Factor (EGF)IBA 08/2015 - 12/2004
3	A-Form DNA (A-DNA)IBA 08/2013 - 11/2003
2	N-methyladenosineIBA 01/2022 - 01/2021
2	NucleotidesIBA 01/2020 - 11/2003
2	LigandsIBA 01/2020 - 12/2004
2	Monocarboxylic Acid TransportersIBA 04/2019 - 03/2018
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 08/2017
2	PolyaminesIBA 01/2019 - 01/2018
2	Methylenetetrahydrofolate Dehydrogenase (NADP) (Dehydrogenase, Methylenetetrahydrofolate)IBA 12/2018 - 01/2017
2	Serine (L-Serine)FDA Link 04/2017 - 01/2017
2	HydrolasesIBA 04/2017 - 02/2003
2	Histones (Histone)IBA 11/2016 - 11/2003
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2016 - 03/2015
2	CytokinesIBA 12/2015 - 05/2013
2	RibonucleotidesIBA 11/2015 - 01/2015
2	HexokinaseIBA 05/2015 - 09/2014
2	Green Fluorescent ProteinsIBA 12/2014 - 12/2014
2	AntibodiesIBA 09/2014 - 04/2014
2	Epithelial Cell Adhesion MoleculeIBA 04/2014 - 04/2013
2	Transforming Growth Factor beta (TGF-beta)IBA 05/2013 - 12/2004
2	Aldehyde DehydrogenaseIBA 04/2013 - 04/2013
2	Cadherins (E-Cadherin)IBA 07/2012 - 09/2010
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2011 - 10/2008
2	teleocalcinIBA 01/2011 - 10/2010
2	Tumor Biomarkers (Tumor Markers)IBA 12/2010 - 07/2009
2	Matrix Metalloproteinases (MMPs)IBA 12/2010 - 12/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2010 - 12/2004
2	AntigensIBA 02/2010 - 07/2009
2	Caspase 3 (Caspase-3)IBA 07/2009 - 10/2004
2	CamptothecinIBA 12/2008 - 05/2007
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 12/2008 - 05/2007
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 12/2008 - 10/2008
2	NitrosaminesIBA 04/2008 - 11/2004
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2006 - 05/2005
2	ErbB Receptors (EGF Receptor)IBA 01/2006 - 12/2004
2	Histone Deacetylase InhibitorsIBA 01/2006 - 05/2005
2	Phosphotransferases (Kinase)IBA 01/2006 - 03/2005
2	romidepsin (FK228)FDA Link 01/2006 - 05/2005
2	DepsipeptidesIBA 01/2006 - 05/2005
2	Tyrosine Kinase InhibitorsIBA 01/2006 - 12/2004
2	ZincIBA 10/2004 - 01/2003
1	Peptides (Polypeptides)IBA 10/2022
1	Myosins (Myosin)IBA 10/2022
1	Myosin Type IIIBA 10/2022

Therapy/Procedure

33	Therapeutics 04/2022 - 03/2004
17	Drug Therapy (Chemotherapy) 06/2021 - 07/2010
8	Radiotherapy 01/2022 - 09/2010
5	Precision Medicine 04/2022 - 04/2017
4	Lasers (Laser) 06/2012 - 05/2007